News | Radiation Therapy | October 25, 2017

MR-Guided Radiotherapy Prolongs Median Survival for Inoperable, Locally Advanced Pancreatic Cancer

Study indicates higher dosing enabled by MR-guidance combined with daily on-table adaptation led to significant potential clinical benefits for pancreatic cancer patients

MR-Guided Radiotherapy Prolongs Median Survival for Inoperable, Locally Advanced Pancreatic Cancer
MRIdian MRI-guided radiotherapy overall survival for pancreatic cancer patients

Early clinical data suggests nearly 2X prolonged median survival for inoperable, locally advanced pancreatic cancer with MRIdian MR-Guided Radiation Therapy. Image from “Higher Maximum Biological Effective Dose Utilizing Adaptive MRI Guided Radiation Therapy Improves Survival of Inoperable Pancreatic Cancer Patients. Rudra S, Jiang N, Rosenberg S, Olsen J, Lagerwaard F, Bruynzeel A, Parikh P, Bassetti, M, Lee P, ASTRO 2017”

October 25, 2017 — ViewRay Inc. announced outcomes data presented during the recent 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San Diego. This data highlighted compelling early results using the company's magnetic resonance imaging (MRI)-guided MRIdian radiation therapy system for the treatment of inoperable, locally advanced pancreatic cancer.

MRIdian allows clinicians to see the tumor and nearby soft-tissue anatomy throughout radiation treatments using real-time diagnostic MR-visualization. As a result, MRIdian's on-table adaptive radiation therapy allows doctors to respond to subtle anatomical changes observed on a day-to-day basis and reshape the dose to better match the current contours of the tumor. By more accurately targeting the tumor, and reducing treatment radiation dose to surrounding organs such as the duodenum, small bowel, stomach and liver, a higher and potentially more effective radiation dose may be delivered without increasing the risks of side effects and complications for the patient.

As featured in the ASTRO Scientific Session poster titled "High Dose Adaptive MRI Guided Radiation Therapy Improves Overall Survival of Inoperable Pancreatic Cancer," key data points and findings from the presentation include the following:

  • The study detailed a retrospective review of 42 locally-advanced pancreatic cancer patients treated with MRIdian at four institutions (University of California Los Angeles, University of Wisconsin, VU University Medical Center, Washington University);
  • The authors examined survival and toxicity rates for two unique cohorts of patients. One sample received a higher biologically effective dose (maxBED10 >90), primarily enabled by MRIdian MR-guided on-table adaptive radiotherapy. The other sample received a lower, more conventional biologically effective dose (maxBED10 <90), using non-adaptive therapy;
  • The cohort receiving a higher dose demonstrated a near doubling of median overall survival (Kaplan-Meier estimated median overall survival of 27.8 months compared to 14.8 months); and
  • Patients treated with higher radiation doses reported no grade 3 or higher toxicities (0 percent). In comparison, those patients receiving lower doses via non-adaptive treatments experienced 15.8 percent grade 3 or higher toxicities.

"High-definition MR now enables oncologists to detect the slightest anatomical changes that occur from one day to the next and in real-time while the patient is being treated. Coupled with new adaptive radiation therapy software tools, we create new customized plans in minutes, all while the patient is on the treatment table," said Percy Lee, M.D., senior author and associate professor and vice chair of education for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA. "The data presented at the 2017 ASTRO Annual Meeting suggests that higher radiation doses with adaptive MR guided radiation therapy may improve survival in pancreatic cancer while maintaining a very favorable toxicity profile. These outcomes warrant further investigations."

The early results highlighted above, along with other data obtained using MRIdian, will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer. The trial will be conducted by ViewRay's Clinical Cooperative Think Tank (C2T2), a group of MRIdian medical institutions focused on evidence gathering to support MR-guided radiation therapy.

For more information: www.viewray.com

Related MRI-Guided Radiotherapy Content

WEBINAR: Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation

Related Content

Guerbet Signs Agreement With Icometrix for Exclusive Distribution of Icobrain
News | Neuro Imaging | October 16, 2019
Guerbet announced it has signed an exclusive agreement with Icometrix for the distribution in France, Italy and Brazil...
Subtle Medical Receives FDA 510(k) Clearance for AI-powered SubtleMR
Technology | Artificial Intelligence | October 16, 2019
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtleMR. SubtleMR...
Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Sponsored Content | Case Study | Magnetic Resonance Imaging (MRI) | October 16, 2019
Since the introduction of magnetic resonan...
Videos | Radiation Oncology | October 11, 2019
Lorraine Drapek, DNP, nurse practitioner, radiation oncology, GI service,...
Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Feature | Magnetic Resonance Imaging (MRI) | October 09, 2019 | By Jeff Zagoudis
Sponsored Content | Whitepapers | Clinical Trials | October 09, 2019
A 2019 N G PX REPORT
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 03, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
AI Accurately Detects Key Chest X-Ray Pneumonia Findings Within 10 Seconds
News | Artificial Intelligence | September 30, 2019
Researchers from Intermountain Healthcare and Stanford University say 10 seconds is about how quickly a new system they...